<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2003">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377334</url>
  </required_header>
  <id_info>
    <org_study_id>RESCOVID</org_study_id>
    <nct_id>NCT04377334</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)</brief_title>
  <official_title>Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone
      marrow-derived human mesenchymal stem (stromal) cells (MSCs) and whether this therapy has an
      influence on the resolution processes in ARDS patients infected with Severe acute respiratory
      syndrome coronavirus 2 (SARS-CoV-2).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lung injury score</measure>
    <time_frame>day 10</time_frame>
    <description>improvement of lung injury score (LIS), 0-16 points, severity increasing with higher points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-dimers</measure>
    <time_frame>day 0, 1, 2, 3, 10 and 15</time_frame>
    <description>D-dimers blood levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phenotype</measure>
    <time_frame>day 0, 1, 2, 3, 10 and 15</time_frame>
    <description>distribution of phenotypes of immune cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pro-resolving lipid mediators</measure>
    <time_frame>day 0, 1, 2, 3, 10 and 15</time_frame>
    <description>Levels of specialized pro-resolving lipid mediators within alveolar macrophages and bronchoalveolar lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytokines</measure>
    <time_frame>day 0, 1, 2, 3, 10 and 15</time_frame>
    <description>Cytokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemokines</measure>
    <time_frame>day 0, 1, 2, 3, 10 and 15</time_frame>
    <description>Chemokine concentration within bronchoalveolar lavage and Serum prior and after MSC infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>day 10 and 28</time_frame>
    <description>Survival at 10 days and 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extubation</measure>
    <time_frame>day 28</time_frame>
    <description>Time to removal of endotracheal tube</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte subpopulations</measure>
    <time_frame>day 0, 3, 5 and 10</time_frame>
    <description>lymphocyte subpopulations in peripheral blood by flow cytometry prior and after MSC infusion (day 0,3,5,10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2-specific antibody titers</measure>
    <time_frame>day 0, 5 and 10</time_frame>
    <description>evaluate SARS-CoV-2-specific antibody titers in the serum of patients prior and post MSC infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complement molecules (C5-C9)</measure>
    <time_frame>day 0, 5 and 10</time_frame>
    <description>evaluate levels of complement molecules (C5-C9) in the serum of patients prior and post MSC infusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>ARDS</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>MSC Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC</intervention_name>
    <description>infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells</description>
    <arm_group_label>MSC Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19-positive subject

          -  Horowitz index ≤ 200

          -  Bilateral opacities on frontal chest radiograph, and

          -  requirement for positive pressure ventilation via an endotracheal tube or non-invasive
             ventilation

          -  no clinical signs of left atrial hypertension detected via echocardiography, or if
             measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mmHg.

          -  Subject's Age ≥ 18 years

        Exclusion Criteria:

          -  COVID-19-negative subject

          -  Subject's Age &lt; 18 years

          -  More than 7 days since initiation of mechanical ventilation

          -  Patient, surrogate or physician not committed to full intensive care support.

          -  Positive Pregnancy test at the time of screening.

          -  Patients dependent on the sponsor, investigator and their employees, as well as
             persons dependent on the manufacturer of the investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rosenberger, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Rosenberger, Prof.</last_name>
    <phone>+49707129</phone>
    <phone_ext>86622</phone_ext>
    <email>peter.rosenberger@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Rosenberger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Rosenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

